In the latest quarter, 16 analysts provided ratings for Intra-Cellular Therapies (NASDAQ:ITCI), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...
Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for approximately $14.6 billion, paying $132 per share in cash. The acquisition includes CAPLYTA® (lumateperone), the only ...
Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback